We claim:

1. A formulation comprising

5

- fenofibric acid, or a physiologically acceptable salt or derivative thereof, and optionally other active substances;
- ii) a binder component comprising at least one enteric binder; and optionally
 - iii) other physiologically acceptable excipients.
- 15 2. The formulation as claimed in claim 1, wherein the physiologically acceptable derivative of fenofibric acid is fenofibrate.
- 3. The formulation as claimed in claim 1, wherein fenofibric acid, the physiologically acceptable salt or derivative thereof is in the form of a molecular dispersion.
 - 4. The formulation as claimed in claim 1, wherein the enteric binder is an enteric polymer.

25

30

- 5. The formulation as claimed in claim 4, wherein the enteric polymer is selected from hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, carboxymethylethylcellulose, cellulose acetate phthalate, cellulose acetate trimellitate and carboxymethylcellulose sodium.
- 6. The formulation as claimed in claim 4, wherein the enteric polymer is selected from copolymers based on (meth)acrylic acid and at least one alkyl (meth)acrylic acid ester.
 - 7. The formulation as claimed in claim 6, wherein the alkyl (meth)acrylic acid ester is methyl methacrylate.
- 40 8. The formulation as claimed in claim 6, wherein the copolymer has a ratio of free carboxyl groups to esterified carboxyl groups of around 2:1 to 1:3.
- 9. The formulation of claim 8, wherein the ratio is around 1:1.

WO 2004/054568 PCT/EP2003/014331

30

- 10. The formulation as claimed in claim 1, wherein the formulation comprises
- i) 5 to 60% by weight, preferably 7 to 40% by weight and in particular 10 to 30% by weight of active substance component;
 - ii) 20 to 95% by weight, preferably 30 to 90% by weight and in particular 40 to 85% by weight, of binder component;
 - iii) 0 to 75% by weight, preferably 1 to 60% by weight and in particular 5 to 40% by weight, of other physiologically acceptable excipients.
- 15 11. The formulation as claimed in claim 1, wherein the enteric binder preferably constitutes 5 to 95 % by weight, more preferably 10 to 70 % by weight and, in particular, 30 to 60 % by weight of the binder component (ii).
- 20 12. The formulation as claimed in claim 1, wherein the content of active substance component (i) relative to binder component (ii) is from 1 to 50% by weight, preferably 10 to 40% by weight and in particular 20 to 30% by weight.
- 25 13. The formulation as claimed in claim 1, comprising
 - i) fenofibric acid or fenofibrate;

10

- ii) at least one binder selected from enteric polymers; and
 optionally
 - iii) other physiologically acceptable excipients, especially a flow regulator, e.g. highly disperse silica gel.
- 35 14. The formulation as claimed in any one of the preceding claims, obtainable by melt extrusion of a mixture comprising fenofibric acid, a physiologically acceptable salt or derivative thereof, binder and optionally other active substances and/or other physiologically acceptable excipients.
- 15. A method for oral administration of fenofibric acid, a physiologically acceptable salt or derivative thereof, comprising administering a formulation as claimed in any one of claims 1 to 14, optionally with the addition of other excipients, as dosage form.

WO 2004/054568 PCT/EP2003/014331

16. Dosage form comprising a formulation as claimed in any one of claims 1 to 14.